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Vitor RR Mendonça1,2, Artur TL Queiroz1, Fabrício M Lopes3,4, Bruno B Andrade5*† and Manoel Barral-Netto1,2,6†Abstract
Background: Plasmodium vivax malaria clinical outcomes are a consequence of the interaction of multiple parasite,
environmental and host factors. The host molecular and genetic determinants driving susceptibility to disease
severity in this infection are largely unknown. Here, a network analysis of large-scale data from a significant number
of individuals with different clinical presentations of P. vivax malaria was performed in an attempt to identify
patterns of association between various candidate biomarkers and the clinical outcomes.
Methods: A retrospective analysis of 530 individuals from the Brazilian Amazon, including P. vivax-infected
individuals who developed different clinical outcomes (148 asymptomatic malaria, 187 symptomatic malaria, 13
severe non-lethal malaria, and six severe lethal malaria) as well as 176 non-infected controls, was performed. Plasma
levels of liver transaminases, bilirubins, creatinine, fibrinogen, C-reactive protein, superoxide dismutase (SOD)-1,
haem oxygenase (HO)-1 and a panel composed by multiple cytokines and chemokines were measured and
compared between the different clinical groups using network analysis.
Results: Non-infected individuals displayed several statistically significant interactions in the networks, including
associations between the levels of IL-10 and IL-4 with the chemokine CXCL9. Individuals with asymptomatic malaria
displayed multiple significant interactions involving IL-4. Subjects with mild or severe non-lethal malaria displayed
substantial loss of interactions in the networks and TNF had significant associations more frequently with other
parameters. Cases of lethal P. vivax malaria infection were associated with significant interactions between TNF ALT,
HO-1 and SOD-1.
Conclusions: The findings imply that clinical immunity to P. vivax malaria is associated with multiple significant
interactions in the network, mostly involving IL-4, while lethality is linked to a systematic reduction of complexity of
these interactions and to an increase in connections between markers linked to haemolysis-induced damage.
Keywords: Malaria, Plasmodium vivax, Biomarkers, Network analysisBackground
The vast majority of human diseases do not result from
single molecular changes, and malaria is certainly
included in this group. Besides factors related to the
Plasmodium parasite itself, malaria is a consequence
of multiple host molecular and genetic alterations
compounded by environmental factors [1]. Most of the
studies in malaria immunopathogenesis are focused on
the identification of one or a small group of candidate* Correspondence: andradebd@niaid.nih.gov
†Equal contributors
5Immunobiology Section, Laboratory of Parasitic Diseases, National Institute
of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
20893, USA
Full list of author information is available at the end of the article
© 2013 Mendonça et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediummolecules related to disease severity. The cytokine bal-
ance seems to influence malaria outcome, with TNF,
IFN-γ and IL-10 emerging as key players in both experi-
mental models and in human observational studies
[2-6]. Recently, host factors associated with oxidative
stress, such as the enzymes superoxide dismutase 1
(SOD-1) and haem oxygenase (HO)-1, as well as
molecules that are linked to metabolic adaptation to iron
overload during malaria-triggered haemolysis, have been
identified as very potent biomarkers to distinguish
individuals developing more severe forms of vivax mal-
aria [7-9]. However, the patterns of interaction between
these multiple factors within the clinical spectrum of
human malaria are largely unexplored. The situation istral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dium vivax, which has been relatively neglected for
many years and recently re-emerged as a potentially le-
thal disease [6,10-13].
The use of a comprehensive approach to exploring the
relationship between groups of molecules likely to be
related to the severity of the disease manifestations may
contribute to a better understanding of the patterns of
susceptibility to disease severity or disease tolerance. In
this study, network analysis of a large dataset from a sig-
nificant number of individuals presenting with different
clinical manifestations of vivax malaria was performed in
an attempt to identify patterns of association between
various candidate biomarkers and the clinical outcomes.
The findings from this exploratory study demonstrate a
new level of complexity connecting several mediators
involved in the immunopathogenesis of vivax malaria.
Methods
Study design and participants
The present study is a retrospective analysis of a databank
containing clinical, epidemiological and immunological
data from 530 individuals from the Brazilian Amazon
(Rondônia, Brazil) recruited between 2006 and 2007, as
part of a project aimed at describing determinants of sus-
ceptibility to vivax malaria that was finalized on 2010. In
this project, both active and passive malaria case detection
were performed. These included home visits in areas of
high transmission (active case detection), and study of
individuals seeking care at the diagnostic centres of Brazil-
ian National Foundation of Health (FUNASA) or in a mu-
nicipal hospital in Buritis, Rondônia, Brazil (passive case
detection). Individuals of both sexes, ranging in age from
five to 70 years, who had resided in the endemic area for
more than six months, were invited to participate. The
details of the recruitment, diagnosis approach and clinical
definitions of asymptomatic infection or severe malaria
caused by P. vivax used in the project were published pre-
viously [6-9,14-17]. The exclusion criteria were as follows:
Plasmodium falciparum infection documented by both
microscopy and nested polymerase chain reaction (PCR),
documented viral hepatitis, chronic alcoholism, human
immunodeficiency virus type 1 infection, yellow fever,
leptospirosis, cancer and chronic degenerative diseases,
sickle cell trait and the use of hepatotoxic or immunosup-
pressant drugs. The malaria diagnosis was made in a
reference centre from the National Foundation of Health
in the endemic area and confirmed with nested PCR as
previously described [14,15,17]. Individuals without
symptoms were actively recruited in their residencies by
active search, mostly in remote riverine communities and
had thick blood smear samples and a small aliquot of
blood in EDTA tubes collected for diagnostic screening by
nested PCR. The diagnosis in those individuals wasperformed after the clinical visit and if a positive test for
malaria was found, a second visit within 30 days was
performed in order to search for appearance of malaria
symptoms. A new sample collection was made and a sec-
ond round of diagnostic tests was performed. Subjects that
remained with positive nested PCR for Plasmodium within
this period of 30 days and presented no malaria-related
symptoms, such as fever (axillary temperature >37.8°C),
chills, sweats, myalgia, arthralgia, strong headaches, nau-
sea, vomiting, jaundice, and severe asthenia during this
period were considered as asymptomatic malaria cases.
During the first clinical visit (previously to the results of
the diagnostic tests) all the asymptomatic individuals
received counselling and were oriented to seek for health
care in a malaria reference centre in case symptoms
appeared during the period between the 2 clinical visits.
After the second clinical visit, all the patients that had
positive malaria screening with microscopy and/or nested
PCR were treated following the treatment guidelines of
the Brazilian Ministry of Health. The plasma samples used
to assess the biomarkers were collected during the second
clinical visit, before the initiation of anti-malarial drugs.
Symptomatic individuals were promptly treated. Data
from a total of 530 individuals were analysed, and the
individuals were stratified into the following categories:
non-infected (n=176), asymptomatic vivax malaria
(n=148), symptomatic vivax malaria (n=187), severe non-
lethal vivax malaria (n=13), and severe vivax malaria
associated with mortality (n=6). The plasma samples
obtained from patients with severe forms of malaria,
including the cases that eventually died during the follow
up were collected at the hospital admission and the
procedures are described elsewhere [6]. Demographic
characteristics of the study participants are shown in the
Table 1.
Ethics statement
Written informed consent was obtained from all par-
ticipants or their legally responsible guardians, and all
clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. The
project was approved by the institutional review board
of the Faculdade de Medicina, Faculdade São Lucas,
Rondônia, Brazil, where the study was performed.
Laboratory measurements
Several mediators were selected based on the assessment
of the overall inflammatory status and immune responses
in malaria. All the biomarkers that were measured in all
the patients, and were contained in the databank, were
included in the analysis and no pre-selection was done.
Plasma measurements of aspartate amino-transferase
(AST), alanine amino-transaminase (ALT), total bilirubin,
direct bilirubin, creatinine, fibrinogen and C-reactive









n=176 n=148 n=187 n=13 n=6
Male (%) 72 (40.9) 70 (47.3) 93 (49.7) 7 (53.8) 3 (50.0) 0.504
Age - years <0.001
Median 32 40 33 22 27
IQR 24-45 32-49 27-42 16-30 13-44
Years residing in the area <0.001
Median 12.6 11.8 7.6 2.6 3
IQR 3.2-14.8 3.5-16.4 0.6-10.1 0.5-4.8 0.3-5.2
Parasites/μL <0.001
<500 176 145 49 0 0
(100%) (98.0%) (26.2%)
500-5,000 0 3(2.0%) 84 4 1
(44.9%) (30.8%) (16.7%)
5,001-50,000 0 0 50 6 3
(26.7%) (46.1%) (50%)
>50,000 0 0 4 3 2
(2.1%) (23.1%) (33.3%)
IQR: interquartile range.













P value P value
1 2
n=176 n=148 n=187 n=13 n=6
IL-1β 5.7 4.0 11.4 7.6 15.54 <0.001 <0.001
pg/mL (3.5-17) (2.7-7.8) (6.2-25.5) (6.6-23.8) (4.8-29.3)
IL-4 23.4 22.1 29.89 30.1 36.4 <0.001 0.008
pg/mL (12.3-40) (12-34.4) (16.8-102) (18.5-41) (18-115)
IL-6 8.4 10.3 69.2 78.5 101.2 <0.001 <0.001
pg/mL (5.2-20) (1.5-21.4) (23.9-105.5) (56-105) (41-140)
IL-8 6.3 3.6 26.0 12.4 66.8 <0.001 <0.001
pg/mL (4.7-11) (2.3-9.2) (5.9-102.5) (6.1-66.7) (15-211)
IL-10 12.0 62.0 125.0 140.2 110.5 <0.001 0.349
pg/mL (7-20.4) (11.3-89.6) (65.3-455.1) (85-550) (79-134)
IL-12p70 7.7 13.5 20.7 12.7 10.0 <0.001 0.520
pg/mL (4.9-16) (7.7-18.3) (12.4-30.5) (5.1-20.9) (5-15)
IFN-γ 32.1 54.3 103.4 212.5 181.6 <0.001 <0.001
pg/mL (11-62) (23.6-142.0) (42.0-324.0) (80-465) (65-357)
TNF-α 0 2.4 38.5 57.2 31.95 <0.001 <0.001
pg/mL (0–10.5) (0–10.3) (18.1-80.5) (32.5-84) (19-76.8)
TGF-β 23.8 89.8 111.1 48.6 40.2 <0.001 <0.001
pg/mL (1.3-31) (39.4-193.8) (84.5-364.7) (32-58.6) (26-44.5)
Note: Data represent median values and interquartile ranges. P value 1 was obtained using Kruskal-Wallis test, whereas P value 2 was calculated using Linear
trend post test.
IQR: interquartile range.
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Faculdade São Lucas and at the Pharmacy School (Federal
University of Bahia, Brazil). The cytokines IL-1β, IL-4, IL-
6, IL-8, IL-10, IL-12p70, IFN-γ, TNF and the chemokines
CCL2 (MCP-1), CCL5 (RANTES), CXCL9 (MIG) and
CXCL10 (IP-10) were measured using the cytometric bead
array (CBA) (BD Biosciences Pharmingen, San Diego, CA,
USA). The flow cytometric assay was performed and
analysed by a single operator, and standard curves were
derived from cytokine standards. The experiments were
performed according to the manufacturers’ instructions.
ELISA kits were used to measure the soluble TNF recep-
tor I (sTNF-RI; R&D Systems, Minneapolis, MN, USA),
transforming growth factor (TGF)-β (R&R Systems),
SOD-1 (Calbiochem, San Diego, CA, USA) and HO-1
(Assay Designs, Ann Arbor, MI, USA) according to the
manufacturers’ protocols. In order to compare the distri-
bution of the biomarkers according to the clinical groups,
the laboratory parameters were categorized in cytokines
(Table 2), surrogates of inflammatory damage (Table 3)
and chemokines and other proteins (Table 4).
Network analysis
The inferential network was generated from the values of
each mediator measured in the plasma samples, in which









Total bilirubin mg/dL 0.7 0.8 1
(0.5-1.1) (0.5-1.2) (0.8
Direct bilirubin mg/dL 0.3 0.4 0
(0.2-0.4) (0.3-0.8) (0.3
Indirect bilirubin mg/dL 0.4 0.3 0
(0.3-0.6) (0.2-0.4) (0.4
AST U/L 43.3 56.4 1
(34-56.3) (35.5-87.5) (81.5
ALT U/L 40.9 44.9 1
(33.5-54) (32-69.4) (123
Creatinine mg/dL 1.2 1.2 1
(1.1-1.3) (1.0-1.3) (1.2
CRP mg/L 5.2 7.9 1
(3.8-9.7) (4.8-12.3) (8.2
Fibrinogen mg/dL 234.0 302.3 37
(198-305) (210.4-377.5) (234
Note: Data represent median values and interquartile ranges. P value 1 was obtaine
trend post test.
CRP: C-reactive protein.clinical classification of the subjects were based on the dis-
ease outcomes. The systemic levels of each mediator were
input in the DimReduction software [18]. As a result, the
DimReduction software selected the patterns of distribu-
tion of the mediators associated with each clinical group.
Moreover, the same software was applied to identify links
of interaction between the mediators. Following this ap-
proach, each mediator is selected as a target and the
DimReduction software performs a search within the
other mediators for those that are associated with the tar-
get in terms of entropy. As a result, the features related to
the selected target are linked. This process is repeated by
considering each mediator at a time and the result is
the inferred network among the input values. The
DimReduction default parameters values were kept fixed
during all the experiments.
In order to analyse the structure of the biomarker
networks, the network density was adopted, which is, in
the context of this work, the ratio of the number of
edges inferred in the network over total number of pos-
sible edges between all pairs of nodes. The density meas-
ure is defined as follows: density = L/(N (N-1)/2), in
which L is the number of observed edges and N is the
total number of the nodes in the network. The density is
normalized, ranging between 0 (no edges in the net-









P value P value
1 2
187 n=13 n=6
.2 1.8 2.1 <0.001 <0.001
-1.9) (1.5-2.5) (1.2-3.2)
.4 0.6 1.1 <0.001 <0.001
-0.8) (0.4-1.3) (0.3-1.7)
.7 1.1 1.2 <0.001 <0.001
-1.2) (0.8-1.3) (0.9-1.3)
67 201.0 268.4 <0.001 <0.001
-506) (87-302) (160-340)
80 201.1 278.8 <0.001 <0.001
–438) (190-304) (175-342.9)
.3 1.7 2.4 <0.001 <0.001
-1.4) (1.3-2.5) (1.9-2.5)
5.5 13.2 34.4 <0.001 <0.001
-32.8) (6.7-47.5) (16.4-50.7)
4.5 415.5 437.7 <0.001 <0.001
-485.6) (374-498) (348.5-530.8)
d using Kruskal-Wallis test, whereas P value 2 was calculated using Linear














P value P value
1 2
n=176 n=148 n=187 n=13 n=6
CCL2 86.0 85.2 65.8 64.7 87.9 0.117 0.207
ng/mL (21-176) (18-161.6) (23.0-145.6) (43-127) (34.7-139)
CCL5 27.0 24.4 25. 3 26.1 36.7 0.007 0.156
μg/mL (15-45.7) (13.4-38) (15.8-70.2) (20-38.7) (25.4-83.2)
CXCL9 0.3 0.5 2.2 3.5 4.6 <0.001 <0.001
ng/mL (0.2-0.5) (0.3-0.8) (0.4-9.4) (0. 6-12.5) (0.8-9.9)
CXCL10 88.0 19.4 77.4 117.7 183.3 <0.001 <0.001
pg/mL (25-198) (10.2-25.0) (25.3-360.7) (28-564) (30.0-395.5)
sTNF-RI 0.2 0.5 0.6 0.8 2.2 <0.001 <0.001
ng/mL (0.1-0.4) (0.4-0.6) (0.4-0.7) (0.7-0.9) (1.7-3.1)
SOD-1 4.2 6.0 26.0 72.6 82.4 <0.001 <0.001
ng/mL (2.6-6.8) (3.6-10) (18.8-34.0) (71-80.4) (76.6-100.5)
HO-1 29.1 29.5 35.5 42.9 49.2 <0.001 <0.001
ng/mL (25.8-32) (26.3-35.2) (29.7-44.8) (38.5-45) (48.4-57.3)
Note: Data represent median values and interquartile ranges. P value 1 was obtained using Kruskal-Wallis test, whereas P value 2 was calculated using
Linear trend post test.
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In the exploratory analysis of the data, frequency
tables were constructed and the Chi-square test was
applied to evaluate the association between qualitative
variables. The quantitative variables were tested for
Gaussian distribution within the total sample using
D’Agostino and Pearson omnibus normality test. The
variables with normal distribution were compared be-
tween the groups by one-way ANOVA with linear
trend or Bonferroni’s multiple comparisons post-test.
Further analysis were based on non-parametric tests
only, considering the small number of individuals
located in the two groups with severe vivax malaria.
In this context, Kruskal Wallis test was used to assess
the differences between the clinical groups and
Mann-Kendall test was used to estimate liner trends.
Only results from the non-parametric analyses are
shown. Correlations between parasitaemia and the
biomarkers from the networks were assessed using
the Spearman rank test. For each analysis, P<0.05 was
considered statistically significant. The graphics for
the network analysis were customized using the
Ingenuity Systems Pathway Analysis software (Ingenu-
ity Systems, Redwood City, CA, USA). The statistical
analyses were performed using the programs Graph-
Pad Prism 5.0 (GraphPad Software Inc, USA), STATA
9.0 (StataCorp, TX, USA), and JMP 9.0 (SAS, Cary,
NC, USA).Results
The plasma concentrations of most mediators measured
were statistically different among the clinical groups,
and many markers displayed linear trend to increase or
decrease according to the degree of disease severity, as
detailed in the Tables 2, 3 and 4. In the network analysis,
densities of biomarker networks were observed, ranging
between 0.021 and 0.032 in the different groups (Figure 1
and Figure 2A). The groups of non-infected individuals
and those with asymptomatic malaria presented higher
connectivity among the molecules, 0.030 and 0.032
respectively, compared to the groups of individuals
with symptomatic infection (symptomatic malaria: 0.023;
non-lethal severe disease: 0.021; and lethal malaria:
0.027) (Figure 2A).
In the group of non-infected individuals, CCL5 and
CXCL9 had several significant interactions, and the
latter was linked to the regulatory cytokines IL-10 and
IL-4. In addition, CRP, ALT and IL-10 also presented
relatively high connectivity, arguing that a fine tune of
interactions involving these markers may influence the
resistance against P. vivax infection. In those individuals
in which infection did not lead to the onset of symp-
toms, the number of significant interactions was similar
to the group of non-infected people (19 significant hits
in the group of uninfected individuals and 18 hits in
asymptomatic malaria), but the number of associations
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Disease severity








to P. vivax 
with repetitive disease episodes
Complexity of the networks
F
Figure 1 Networks of candidate biomarkers during Plasmodium vivax malaria. Plasma levels of several biomarkers of inflammation, tissue
damage and oxidative stress were measured in 176 non-infected healthy individuals (A) and in 148 with asymptomatic infection (B), 187 with
mild disease (C), 13 with severe non-lethal malaria (D) and six patients who died with Plasmodium vivax infection within seven days of
hospitalization (E). The colours shown for each symbol represent the fold variation from the median values (log transformed) calculated for each
marker. Each connecting line represents a significant interaction (P<0.05) detected by the network analysis using the DimReduction software. In
(F), a summary model of the results with regard to the complexity of the networks in the context of the natural history of malaria is illustrated.
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http://www.malariajournal.com/content/12/1/69greatly increased in these individuals, leading to a totally
different pattern of connectivity in the network (Figure 1).
In contrast, the patterns of connections between the
mediators seen in the groups of individuals with symp-
tomatic malaria were dramatically diverse than in the
groups without the disease. The group of subjects with
mild malaria displayed a substantial loss of the number
of significant interactions in the network and the pro-
inflammatory cytokines IFN-γ, TNF and CCL5 had the
highest number of connections (Figure 1). IFN-γ was
associated with indirect bilirubin, creatinine, AST
and TNF, arguing that this cytokine could be driving
inflammation (Figure 1). A number of other significant
connections were detected between pro-inflammatory
mediators, such as IL-12 and CXCL9. TNF-α was
associated with IFN-γ, sTNF-RI, SOD-1 and HO-1,implying a potential interplay between those mediators
in the pathogenesis of malaria-related symptoms. Intri-
guingly, the number of significant interactions and
the overall complexity of networks were systematically
reduced in the group of patients with severe forms of
malaria (Figure 1). In the group of individuals who
survived severe malaria, TNF, IL-4 and direct bilirubin
seemed to have a distinguished pattern of connections,
albeit, no clear clusters were evident and there was over-
all low connectivity between the markers studied. More-
over, in the group of individuals that succumbed to
infection and died, TNF, ALT, HO-1, SOD-1, IL-10, IFN-
γ and indirect bilirubin displayed more connectivity with
other biomarkers, which caused a small increase in the
complexity of the network when compared to the group










































































































positive correlatins with parasitaemia 
negative correlations with parasitaemia
-2 -1.6-1.2 -0.8-0.4 0 0.4 0.8 1.2 1.6 2
Expression scale
***
Figure 2 Associations between Plasmodium vivax parasitaemia and host biomarkers. (A) The distribution of P. vivax parasitaemia in
different clinical groups is shown in red symbols (geometric means and 95% confidence intervals) whereas the values for network densities are
shown as black bars. The variation of parasitaemia according to the malaria clinical severity was assessed using the Mann-Kendall test for linear
trend (*** P<0.001). Statistically significant correlations between parasitaemia and different biomarkers are shown in (B) for the group of
individuals with non-lethal severe malaria and in (C) for the group of patients that died during hospitalization. The correlations were assessed
using the Spearman rank test. The correlations involving parasitaemia shown in (B) and (C) are plotted on top of the host interactome.
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strong linear trend to increase according to the disease
clinical severity in the study population (Table 1 and
Figure 2A), the potential associations between parasit-
aemia levels and the pattern of expression of the differ-
ent biomarkers from the networks were investigated in
the groups of patients with elevated morbidity. In the
group of individuals presenting with severe non-lethal
malaria, parasitaemia displayed significant positive asso-
ciations with TNF, sTNF-RI, IFN-γ, IL-10, CXCL9,
CXCL10, SOD-1 and HO-1, while negatively correlated
with the chemokines IL-8 and CCL2 (Figure 2B). Inter-
estingly, the number of significant associations involving
parasitaemia was greatly reduced in the group of
patients that died with severe vivax malaria (Figure 2C).
The positive correlations involving TNF and IFN-γ
persisted in this group of highly susceptible patients who
died, while the regulatory cytokines IL-10 and TGF-β
were negatively correlated with parasitaemia (Figure 2C).
Discussion
The present study evaluated for the first time the density
and complexity of the network of interactions between
several markers strongly associated with host immune
responses in their relationship with markers of tissue in-
jury against P. vivax malaria in the context of the disease
clinical outcomes. The results presented herein demon-
strate that non-infected endemic controls exhibit a richand dense network of interactions among immune-related
markers and those involved in pathology. Such network is
drastically deranged in symptomatic individuals but it is
reconstituted in asymptomatic individuals. In this context
it is stressed that asymptomatic infection is a state
achieved by long-time residents in endemic areas and
strongly related to several previous episodes of symptom-
atic malaria [6] being thus related to the development of a
partial resistance to infection and/or tolerance to disease
[19]. As a consequence, the onset of symptoms is
prevented by limiting parasite burden and controlling in-
flammation. Such asymptomatic carriers develop just
enough immunity to protect them from malarial illness,
but not from malarial infection [1]. In the present study,
asymptomatic carriers displayed the highest density values
in the networks interactions, which argue that there may
exist a complex regulatory mechanism behind the suscep-
tibility to infection and tolerance and/or resistance against
malaria. The network density values described in
this study are similar to another protein-protein and
metabolism-associated networks described previously in
many other clinical contexts [20], which suggests that im-
mune system may display similar homeostatic responses
involving intrinsically complex regulatory pathways.
Additional studies assessing network analysis of the im-
mune responses in other infections and clinical contexts
are needed to identify potential key common factors that
could be targeted in a therapeutic approach.
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cative of an important role for this chemokine in exposed
but non-infected individuals since it correlates with pro-
tection against malaria in volunteers vaccinated by the
circumsporozoite protein-based vaccine [21]. In addition,
both IL-10 and IL-4 had significant connections with
CXCL9, which also interacted with CCL2 and IFN-γ in
those non-infected and with symptomless P. vivax infec-
tion, respectively. These interactions evidence a protective
role of IL-4 and IL-10 through a modulatory effect on
these pro-inflammatory mediators. Support for this
modulatory hypothesis comes from the description that
IL-10 and IL-4 can directly down regulate pro-
inflammatory cytokines such as IL-6, TNF and IL-1β and
prevent severe forms of malaria [22-26]. Studies with
mouse macrophages in vitro argue that IL-4 suppresses
the expression of CXCL9 and other IFN-γ inducible genes
via STAT 6 signalling [27]. Although interesting, a role of
a direct modulatory link between IL-10, IL-4 and CCL2
and/or CXCL9 and pro-inflammatory status of Plasmo-
dium infected individuals is yet unexplored mechanistic-
ally and deserves further investigation.
Extensive research has been done in the identification
of factors associated with severe forms of malaria, with
significant contributions to the understanding of the dis-
ease pathogenesis. In the present study and not surpris-
ingly, IFN-γ and TNF and the chemokine CCL5 were
demonstrated to be crucial biomarkers in the network
profile of those individuals with mild vivax malaria.
CCL5 is a chemokine involved in the generation of in-
flammatory cellular infiltrates and its low levels are
linked to cerebral malaria and severe malarial anaemia,
maybe as consequence of thrombocytopaenia and the in-
fluence of haemozoin production [28-30]. The connect-
ivity between IL-12 and CXCL9 seen in the networks
from mildly symptomatic patients is also observed in the
context of cancer therapy, in which administration of
IL-12 increases the expression of CXCL9 in peripheral
blood mononuclear cells as a response against the
tumour [31,32]. Interactions involving CXCL9 had an
intriguing pattern between the study groups. This
chemokine was more associated with regulatory cyto-
kines in the group of non-infected controls, which may
suggest a potential influence over the resistance to infec-
tion. On the other side, CXCL9 was linked to pro-
inflammatory IL-12 within symptomatic subjects, which
may be associated with the onset of clinical disease.
While networking the immune response in lethal cases
of severe P. vivax malaria, it was found an important
role for HO-1, an enzyme primarily responsible for the
host detoxification from harmful free haem and which
produces carbon monoxide (CO), free iron and biliver-
din. Higher HO-1 levels were described in patients with
symptomatic vivax malaria and this enzyme maycontribute (both very high and low levels) to disease
severity [8,33]. Lower expression of HO-1 may result in
greater availability of free haem resulting in severe mal-
aria, while high expression of HO-1 could lead to
increased synthesis of free iron, which also can be harm-
ful as can promote oxidative damage [33]. Furthermore,
SOD-1, previously associated with P. vivax malaria [7],
displayed connectivity only in the groups of patients
with symptomatic disease, especially in those individuals
who died upon infection. Accumulation of SOD-1 with-
out a compensatory elevation of catalase of glutathione
enzymes could lead to accumulation of H2O2 and the
production of more free radicals by Fenton’s reaction
[34]. Indeed, it has been described that both glutathione
and catalase might be reduced during severe malaria
[35] and high levels of SOD-1 could lead to the exacer-
bation of the oxidative stress and inflammation, aggra-
vating the outcome of the disease. In addition, the
release of haem during malaria erythrocytic cycle
reduces the production of anti-inflammatory prostaglan-
din E2 and TGF-β from mononuclear cells via SOD-1
[16]. Thus, SOD-1 connectivity seen herein in severe
malaria patients seems to be a response against the high
production of deleterious haem during the robust intra-
vascular haemolysis observed in severe malaria.
Furthermore, TNF, IFN-γ and IL-10 also had important
interactions in individuals who succumbed to malaria in-
fection. IL-10 seems to modulate Th1-type responses to
Plasmodium antigens by downregulating TNF, and IFN-γ
levels by dampening the release of IL-12p70, thus resulting
in an impaired immune response that may lead to lethality
[5,36]. However, it has also been described that in cases of
uncontrolled inflammation with high production of pro-
inflammatory mediators may be associated with exhaus-
tion of the protective regulatory responses [6]. In response
to malaria infection, the patterns of expression of multiple
cytokines and the relative balance and interactions be-
tween these factors may be capable of mediating protect-
ive immunity or disease severity depending of the context
[37]. These findings infer that fine-tuning between all the
mediators is extremely important to prevent malaria
lethality.
A major observation from the analysis of the groups of
patients with mild or severe malaria was that the overall
complexity of the networks by means of a number of
significant interactions was reduced while compared to
what was seen in healthy subjects. Intriguingly, in the
group of individuals with asymptomatic malaria, the
complexity of the network was restored and several sig-
nificant interactions were detected, but with a clear cen-
tral role for IL-4. The potential anti-inflammatory effect
of IL-4 in the immune response during malaria is not
yet fully understood [38]. IL-4 seems to assist in
antisporozoite immunity and studies in mice infected
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for the development of CD8+ T lymphocytes [39] and
for the development of a memory response against liver
stage parasite [40]. Furthermore, IL-4 interferes with the
maturation of Th1 cells and can reduce the production
of IFN-γ in some experimental settings [41]. The high
number of interactions between IL-4 and others
biomarkers in asymptomatic individuals highlights a
possible importance of this molecule in modulating the
disease tolerance of individuals constantly exposed to
P. vivax and further investigations should address in
detail the importance of IL-4 in symptomless malaria. A
summary of the results with regard to the complexity of
the network connectivity in the context of the natural
evolution of vivax malaria is shown in Figure 1F.
In the groups of patients with severe malaria, P. vivax
parasitaemia displayed several positive interactions with
previously described inflammatory mediators that par-
ticipate in the immunopathogenesis of malaria, such as
TNF, IFN-γ and IL-10 [1,6,7] in addition to TGF-β. Sur-
prisingly, liver transaminases, bilirubins, creatinine and
CRP were not correlated with parasitaemia. The lack of
direct interactions between parasitaemia and laboratory
surrogates of inflammation-driven tissue injury and oxi-
dative stress suggests that the parasite burden may influ-
ence more stringently the host immune response rather
than induce lethal tissue damage itself. This idea, if
validated in other studies, reinforces the argument that
susceptibility of disease severity in vivax malaria might
be a case of dysfunction of the host homeostatic system
caused by an inflammatory imbalance driven by lack of
resistance against P. vivax.
Conclusion
In summary, the systematic analysis of several mediators
of inflammation measured simultaneously was able to
characterize the overall pattern of immune response of
patients with P. vivax malaria according to disease sever-
ity and clinical outcome. This approach also revealed
other levels of complexity of the disease, involving intri-
cate associations between unique markers, such as TNF,
IFN-γ, IL-4, HO-1 and SOD-1. IL-4, despite being at low
systemic levels, seems to be a central mediator with sev-
eral significant interactions in individuals with asymp-
tomatic malaria. In addition, connectivity involving
CXCL9 and IFN-γ was more prevalent in the groups of
individuals non-infected or with mild manifestations of
the disease while associations involving SOD-1 and
HO-1 were more evident in more severe and lethal
cases. In severe malaria, parasitaemia seems to positively
associate with pro-inflammatory mediators, and the sim-
ultaneous negative correlations involving the regulatory
cytokines IL-10 and TGF-β argue that there is a
deregulated balance of the host immune response that isskewed towards amplification of inflammation. Networ-
king analysis may represent a potential tool to under-
stand the interactions between several mediators in the
context of malarial disease severity. The identification of
critical factors driving malaria pathogenesis can guide
future therapeutic approaches.
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